Main Article Content
Non-operative treatment for Hemangioma involving deeper skin structures extending into the mucosa is usually unsuccessful, since usually no involution will develop. Early surgical planning is important to prevent amblyopia and for the child’s self confidence of their cosmetic appearance later in life.
We present two cases of superior palpebra hemangioma who underwent early surgical treatment.
The first case involves a large hemangioma of the left superior palpebra with severe vision restriction; although later examination was proven that the visual function was still preserved. The second case involves a smaller perioccular lesion. Surgery was performed on both cases. In the larger hemangioma, only partial of tumor was removed by incision at the lid crease and intra-lesion injection of corticosteroids was administered to the remaining tumor.
Advantages of surgical procedure in early rapidly growing stage and in very large hemangioma of upper eyelid; firstly, provides a definitive early treatment; secondly, safe because bleeding was manageable, and third prevent occlusion-related amblyopia. Besides these bene!ts surgery promises added esthetic outcome.
Creative Commons license
Articles opting for open access will be freely available to read, download and share from the time of publication. All open access articles (with the exception of the Research Councils UK funded papers) are published under the terms of the Creative Commons License Attribution-Noncommercial No Derivative 3.0 (CCBY NCND) which allows readers to disseminate and reuse the article, as well as share and reuse of the scientific material. It does not permit commercial exploitation or the creation of derivative works without specific permission. To view a copy of this license visit:http://creativecommons.org/licenses/by-nc-nd/3.0. Authors who are funded by the Research Councils UK and wish to publish their article as open access will be able to publish under the terms of the Attribution 3.0 (CCBY) License. To view of a copy of this license visit:http://creativecommons.org/licenses/by/2.0/.